Heterotopic ossification after total hip arthroplasty (THA) in congenital hip disease: comparison of two different prophylactic protocols
| dc.contributor.author | Pakos, E. E. | en |
| dc.contributor.author | Stafilas, K. S. | en |
| dc.contributor.author | Politis, A. N. | en |
| dc.contributor.author | Tsekeris, P. G. | en |
| dc.contributor.author | Mitsionis, G. | en |
| dc.contributor.author | Xenakis, T. A. | en |
| dc.date.accessioned | 2015-11-24T18:27:32Z | |
| dc.date.available | 2015-11-24T18:27:32Z | |
| dc.identifier.issn | 1699-048X | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/16047 | |
| dc.rights | Default Licence | - |
| dc.subject | congenital hip disease | en |
| dc.subject | total hip arthroplasty | en |
| dc.subject | heterotopic ossification | en |
| dc.subject | radiotherapy | en |
| dc.subject | indomethacin | en |
| dc.subject | high-risk patients | en |
| dc.subject | bone-formation | en |
| dc.subject | ectopic ossification | en |
| dc.subject | predisposing factors | en |
| dc.subject | radiation-therapy | en |
| dc.subject | prevention | en |
| dc.subject | indomethacin | en |
| dc.subject | radiotherapy | en |
| dc.subject | replacement | en |
| dc.subject | irradiation | en |
| dc.title | Heterotopic ossification after total hip arthroplasty (THA) in congenital hip disease: comparison of two different prophylactic protocols | en |
| heal.abstract | We aimed to evaluate retrospectively the efficacy of combined postoperative radiotherapy and indomethacin compared to indomethacin alone for the prevention of heterotopic ossification (HO) in high-risk patients with congenital disease of hip (CDH) undergoing total hip arthroplasty (THA). Fifty-five patients received indomethacin alone (Group A), while 44 patients received the combined protocol (Group B). Patients a parts per thousand yen55 years were enrolled in Group B and those younger than 55 years in Gro up A. Patients were evaluated radiologically for the pre sence of HO 6 months after the operation. The incidence of HO in Group A was 34.5% (95% confidence interval 22.2-48.6%), while the respective incidence in Group B patients was 27.3% (95% CI 15.0-42.8%). The difference was not statistically significant (p=0.5). No significant treatment-related side effects were reported. This is the first study evaluating the impact of HO prophylaxis in an immiscible population of patients with secondary arthritis due to CDH undergoing THA. Further future randomised evidence is required in order to ascertain the observed trend towards improved efficacy of the combined protocol for HO development. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.primary | DOI 10.1007/s12094-009-0322-1 | - |
| heal.identifier.secondary | <Go to ISI>://000263511800009 | - |
| heal.identifier.secondary | http://link.springer.com/content/pdf/10.1007%2Fs12094-009-0322-1.pdf | - |
| heal.journalName | Clinical & Translational Oncology | en |
| heal.journalType | peer reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2009 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιών | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: